Inhibitors of tubulin assembly identified through screening a compound library

Chemical Biology and Drug Design

Volumn 72, Issue 6, 2008, Pages 513-524

  Morgan, Rachel E ^a,c   Ahn, Sunnoo ^a   Nzimiro, Sandra ^a   Fotie, Jean ^a   Phelps, Mitch A ^a   Cotrill, Jeffrey ^a   Yakovich, Adam J ^a   Sackett, Dan L ^b   Dalton, James T ^a   Werbovetz, Karl A ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Leishmania; Library; Screen; Tubulin

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIPROTOZOAL AGENT; BENZENE DERIVATIVE; CYANIDE; OXADIAZOLE DERIVATIVE; OXAZOLE DERIVATIVE; PENTAMIDINE; PODOPHYLLOTOXIN; TUBULIN; VINBLASTINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEISHMANIA TARENTOLAE; MAMMAL; MICROTUBULE ASSEMBLY; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; CERCOPITHECUS AETHIOPS; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; FLUORESCENT DYES; HUMANS; INHIBITORY CONCENTRATION 50; LEISHMANIA; RHODAMINES; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE; TUBULIN; TUBULIN MODULATORS; TUMOR CELLS, CULTURED; VERO CELLS;

KINETOPLASTIDA; LEISHMANIA SP.; LEISHMANIA TARENTOLAE; MAMMALIA; VERMES;

EID: 56649090952     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2008.00729.x     Document Type: Article

References (45)

1. Pellegrini F., Budman D.R. (2005) Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest 23 : 264 273.
2. Zhou J., Giannakakou P. (2005) Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 5 : 65 71.
3. Martin R.J., Robertson A.P., Bjorn H. (1997) Target sites of anthelmintics. Parasitology 114 : S111 S124.
4. Downing K.H., Nogales E. (1998) Tubulin structure: insights into microtubule properties and functions. Curr Opin Struct Biol 8 : 785 791.
5. Kline-Smith S.L., Walczak C.E. (2004) Mitotic spindle assembly and chromosome segregation: refocusing on microtubule dynamics. Mol Cell 15 : 317 327.
6. Amos L.A., Schlieper D. (2005) Microtubules and maps. Adv Protein Chem 71 : 257 298.
7. Wilson L., Miller H.P., Farrell K.W., Snyder K.B., Thompson W.C., Purich D.L. (1985) Taxol stabilization of microtubules in vitro: dynamics of tubulin addition and loss at opposite microtubule ends. Biochemistry 24 : 5254 5262.
8. Skoufias D.A., Wilson L. (1992) Mechanism of inhibition of microtubule polymerization by colchicine: inhibitory potencies of unliganded colchicine and tubulin-colchicine complexes. Biochemistry 31 : 738 746.
9. Himes R.H. (1991) Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules. Pharmacol Ther 51 : 257 267.
10. David-Pfeuty T., Simon C., Pantaloni D. (1979) Effect of antimitotic drugs on tubulin GTPase activity and self-assembly. J Biol Chem 254 : 11696 11702.
11. Lubega G.W., Ochola O.K., Prichard R.K. (2002) Trypanosoma brucei: anti-tubulin antibodies specifically inhibit trypanosome growth in culture. Exp Parasitol 102 : 134 142.
12. Ngô H., Tschudi C., Gull K., Ullu E. (1998) Double-stranded RNA induces mRNA degradation in Trypanosoma brucei. Proc Natl Acad Sci USA 95 : 14687 14692.
13. Chan M.M., Triemer R.E., Fong D. (1991) Effect of the anti-microtubule drug oryzalin on growth and differentiation of the parasitic protozoan Leishmania mexicana. Differentiation 46 : 15 21.
14. Werbovetz K.A., Sackett D.L., Delfín D., Bhattacharya G., Salem M., Obrzut T., Rattendi D., Bacchi C. (2003) Selective antimicrotubule activity of N1-phenyl-3,5-dinitro-N4,N4-di-n-propylsulfanilamide (GB-II-5) against kinetoplastid parasites. Mol Pharmacol 64 : 1325 1333.
15. Bhattacharya G., Herman J., Delfín D., Salem M., Barszcz T., Mollet M., Riccio G., Brun R., Werbovetz K.A. (2004) Synthesis and Antitubulin Activity of N1- and N4-Substituted 3,5-dinitro sulfanilamides against African trypanosomes and Leishmania. J Med Chem 47 : 1823 1832.
16. George T.G., Johnsamuel J., Delfín D.A., Yakovich A., Mukherjee M., Phelps M.A., Dalton J.T., Sackett D.L., Kaiser M., Brun R., Werbovetz K.A. (2006) Antikinetoplastid antimitotic activity and metabolic stability of dinitroaniline sulfonamides and benzamides. Bioorg Med Chem 14 : 5699 5710.
17. George T.G., Endeshaw M.M., Morgan R.E., Mahasenan K.V., Delfín D.A., Mukherjee M.S., Yakovich A.J., Fotie J., Li C., Werbovetz K.A. (2007) Synthesis, biological evaluation, and molecular modeling of 3,5-substituted-N1- phenyl-N4,N4-di-n-butylsulfanilamides as antikinetoplastid antimicrotubule agents. Bioorg Med Chem 15 : 6071 6079.
18. Wu D., George T.G., Hurh E., Werbovetz K.A., Dalton J.T. (2006) Pre-systemic metabolism prevents in vivo antikinetoplastid activity of N1,N4-substituted 3,5-dinitro sulfanilamide, GB-II-150. Life Sci 79 : 1081 1093.
19. Dawson P., Gutteridge W., Gull K.A. (1984) Comparison of the interaction of anhelmintic benzimidazoles with tubulin isolated from mammalian tissue and the parasitic nematode Ascaridia galli. Biochem Pharmacol 33 : 1069 1074.
20. Lacey E. (1990) Mode of action of benzimidazoles. Parasitol Today 6 : 112 115.
21. Robinson M.W., McFerran N., Trudgett A., Hoey L., Fairweather I. (2004) A possible model of benzimidazole binding to beta-tubulin disclosed by invoking an inter-domain movement. J Mol Graph Model 23 : 275 284.
22. Yakovich A.J., Ragone F.L., Alfonzo J.D., Sackett D.L., Werbovetz K.A. (2006) Leishmania tarentolae: purification and characterization of tubulin and its suitability for antileishmanial drug screening. Exp Parasitol 114 : 289 296.
23. Baldwin J., Michnoff C.H., Malmquist N.A., White J., Roth M.G., Rathod P.K., Phillips M.A. (2005) High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J Biol Chem 280 : 21847 21853.
24. St. George S., Bishop J.V., Titus R.G., Selitrennikoff C.P. (2006) Novel compounds active against Leishmania major. Antimicrob Agents Chemother 50 : 474 479.
25. Mackey Z.B., Baca A.M., Mallari J.P., Apsel B., Shelat A., Hansell E.J., Chiang P.K., Wolff B., Guy K.R., Williams J., McKerrow J.H. (2006) Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei. Chem Biol Drug Des 67 : 355 363.
26. Weisman J.L., Liou A.P., Shelat A.A., Cohen F.E., Guy R.K., DeRisi J.L. (2006) Searching for new antimalarial therapeutics amongst known drugs. Chem Biol Drug Des 67 : 409 416.
27. Baniecki M.L., Wirth D.F., Clardy J. (2007) High-throughput Plasmodium falciparum growth assay for malaria drug discovery. Antimicrob Agents Chemother 51 : 716 723.
28. Martyn D.C., Jones D.C., Fairlamb A.H., Clardy J. (2007) High-throughput screening affords novel and selective trypanothione reductase inhibitors with anti-trypanosomal activity. Bioorg Med Chem Lett 17 : 1280 1283.
29. Werbovetz K.A., Brendle J.J., Sackett D.L. (1999) Purification, characterization and drug susceptibility of tubulin from Leishmania. Mol Biochem Parasitol 98 : 53 65.
30. Salem M.M., Werbovetz K.A. (2005) Antiprotozoal compounds from Psorothamnus polydenius. J Nat Prod 68 : 108 111.
31. Hastie S.B. (1991) Interactions of colchicine with tubulin. Pharmacol Ther 51 : 377 401.
32. Hu L., Li Z., Li Y., Qu J., Ling Y.-H., Jiang J., Boykin D.W. (2006) Synthesis and structure-activity relationships of carbazole sulfonamides as a novel class of antimitotic agents against solid tumors. J Med Chem 49 : 6273 6282.
33. Yoshino H.B., Ueda N., Niijima J., Sugumi H., Kotake Y., Koyanagi N., Yoshimatsu K., Asada M., Watanabe T., Nagaau T., Tsukahara K., Iijima A., Kitoh K. (1992) Novel sulfonamides as potential, systemically active antitumor agents. J Med Chem 35 : 2496 2497.
34. Fox E., Maris J.M., Widemann B.C., Meek K., Goodwin A., Goodspeed W., Kromplewski M., Fouts M.E., Medina D., Cho S.Y., Cohn S.L., Krivoshik A., Hagey A.E., Adamson P.C., Balis F.M. (2006) A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 12 : 4882 4887.
35. Berlin J.D., Venook A., Bergsland E., Rothenberg M., Lockhart A.C., Rosen L. (2008) Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma. Clin Colorectal Cancer 7 : 44 47.
36. Gelmon K.A., Belanger K., Soulieres D., Britten C., Chia S., Charpentier D., Chi K., Powers J., Walsh W., Seymour L. (2005) A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130. Invest New Drugs 23 : 445 453.
37. Fox E., Maris J.M., Widemann B.C., Goodspeed W., Goodwin A., Kromplewski M., Fouts M.E., Medina D., Cohn S.L., Krivoshik A., Hagey A.E., Adamson P.C., Balis F.M. (2008) A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res 14 : 1111 1115.
38. Kirby S., Gertler S.Z., Mason W., Watling C., Forsyth P., Aniagolu J., Stagg R., Wright M., Powers J., Eisenhauer E.A. (2005) Phase 2 study of T138067-sodium in patients with malignant glioma: trial of the National Cancer Institute of Canada Clinical Trials Group. Neuro Oncol 7 : 183 188.
39. Mauer A.M., Cohen E.E., Ma P.C., Kozloff M.F., Schwartzberg L., Coates A.I., Qian J., Hagey A.E., Gordon G.B. (2008) A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol 3 : 631 636.
40. Shan B., Medina J.C., Santha E., Frankmoelle W.P., Chou T.-C., Learned R.M., Narbut M.R., Stott D., Wu P., Jaen J.C., Rosen T., Timmermans P.B., Beckmann H. (1999) Selective, covalent modification of β-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc Natl Acad Sci USA 96 : 5686 5691.
41. Yoshimatsu K., Yamaguchi A., Yoshino H., Koyanagi N., Kitoh K. (1997) Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 57 : 3208 3213.
42. Owa T., Yokoi A., Yamazaki K., Yoshimatsu K., Yamori T., Nagasu T. (2002) Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4- methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide. J Med Chem 45 : 4913 4922.
43. Owa T., Okauchi T., Yoshimatsu K., Sugi N.H., Ozawa Y., Nagasu T., Koyanagi N., Okabe T., Kitoh T., Yoshino H. (2000) A focused compound library of novel N-(7-indolyl)benzenesulfonamides for the discovery of potent cell cycle inhibitors. Bioorg Med Chem Lett 10 : 1223 1226.
44. Banerjee M., Poddar A., Mitra G., Surolia A., Owa T., Bhattacharyya B. (2005) Sulfonamide drugs binding to the colchicine site of tubulin: thermodynamic analysis of the drug-tubulin interactions by isothermal titration calorimetry. J Med Chem 48 : 547 555.
45. Liou J.P., Hsu K.S., Kuo C.C., Chang C.Y., Chang J.Y. (2007) A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H- indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule. J Pharmacol Exp Ther 323 : 398 405.